JP2009511452A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009511452A5 JP2009511452A5 JP2008534032A JP2008534032A JP2009511452A5 JP 2009511452 A5 JP2009511452 A5 JP 2009511452A5 JP 2008534032 A JP2008534032 A JP 2008534032A JP 2008534032 A JP2008534032 A JP 2008534032A JP 2009511452 A5 JP2009511452 A5 JP 2009511452A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- immunostimulants
- pharmaceutical composition
- immunostimulant
- hepatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003308 immunostimulating effect Effects 0.000 claims description 18
- 229960001438 immunostimulant agent Drugs 0.000 claims description 16
- 239000003022 immunostimulating agent Substances 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 5
- 108010029697 CD40 Ligand Proteins 0.000 claims description 4
- 229940123189 CD40 agonist Drugs 0.000 claims description 4
- 102100032937 CD40 ligand Human genes 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 101150013553 CD40 gene Proteins 0.000 claims description 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims description 2
- 102100024324 Toll-like receptor 3 Human genes 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 241000711549 Hepacivirus C Species 0.000 claims 3
- 208000005176 Hepatitis C Diseases 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 102000002689 Toll-like receptor Human genes 0.000 description 3
- 108020000411 Toll-like receptor Proteins 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000004041 dendritic cell maturation Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200502446 | 2005-10-07 | ||
| ES200601563A ES2334472B1 (es) | 2006-06-09 | 2006-06-09 | Combinacion inmunoestimuladora para profilaxis y tratamiento de hepatitis c. |
| PCT/ES2006/000554 WO2007042583A1 (es) | 2005-10-07 | 2006-10-05 | Combinación inmunoe s t imuladora para profilaxis y tratamiento de hepatitis c |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009511452A JP2009511452A (ja) | 2009-03-19 |
| JP2009511452A5 true JP2009511452A5 (enExample) | 2009-11-26 |
Family
ID=37942331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008534032A Pending JP2009511452A (ja) | 2005-10-07 | 2006-10-05 | Ｃ型肝炎の予防および治療のための免疫刺激物質の組合せ |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20100047231A1 (enExample) |
| EP (1) | EP1949913B1 (enExample) |
| JP (1) | JP2009511452A (enExample) |
| CN (1) | CN101330928B (enExample) |
| AT (1) | ATE469657T1 (enExample) |
| AU (1) | AU2006301171B9 (enExample) |
| BR (1) | BRPI0616978A2 (enExample) |
| CA (1) | CA2625506C (enExample) |
| CY (1) | CY1110744T1 (enExample) |
| DE (1) | DE602006014720D1 (enExample) |
| DK (1) | DK1949913T3 (enExample) |
| ES (1) | ES2346570T3 (enExample) |
| HR (1) | HRP20100473T1 (enExample) |
| PL (1) | PL1949913T3 (enExample) |
| PT (1) | PT1949913E (enExample) |
| RS (1) | RS51402B (enExample) |
| RU (1) | RU2431499C2 (enExample) |
| SI (1) | SI1949913T1 (enExample) |
| WO (1) | WO2007042583A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2520026T3 (es) | 2006-09-18 | 2014-11-11 | The Board Of Trustees Of The University Of Arkansas | Composiciones y métodos para potenciar respuestas inmunitarias |
| BRPI0818736A2 (pt) * | 2007-10-30 | 2017-06-13 | Univ Arkansas | composições e métodos para intensificar imunorrepostas à bactéria flagelada |
| CN101969990B (zh) | 2007-11-01 | 2014-07-09 | 阿肯色大学评议会 | 增强针对艾美球虫属的免疫反应的组合物和方法 |
| CN102325790A (zh) | 2008-12-03 | 2012-01-18 | 西马生物医学计划公司 | 应用酚可溶性调控蛋白研制疫苗 |
| CN105837691B (zh) | 2009-03-10 | 2021-06-29 | 贝勒研究院 | 靶向抗原呈递细胞的癌症疫苗 |
| CN102811734B (zh) | 2010-01-21 | 2016-02-10 | 阿肯色大学评议会 | 增强免疫应答的疫苗载体和方法 |
| CN102971008B (zh) | 2010-06-09 | 2015-11-25 | 阿肯色大学评议会 | 降低弯曲菌属感染的疫苗和方法 |
| US9603915B2 (en) | 2013-02-14 | 2017-03-28 | The Board of Trustees of the University of Akansas | Compositions and methods of enhancing immune responses to Eimeria or limiting Eimeria infection |
| BR112015023024B1 (pt) | 2013-03-15 | 2022-04-19 | The Board Of Trustees Of The University Of Arkansas | Vetor de vacina e composições farmacêuticas compreendendo o mesmo |
| KR102767638B1 (ko) | 2016-05-03 | 2025-02-20 | 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 | 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5049390A (en) * | 1987-09-02 | 1991-09-17 | Allergy Immuno Technologies, Inc. | Liposome containing immunotherapy agents for treating IgE mediated allergies |
| US6951646B1 (en) * | 1998-07-21 | 2005-10-04 | Genmab A/S | Anti hepatitis C virus antibody and uses thereof |
| AU2001290178A1 (en) * | 2000-08-17 | 2002-02-25 | Tripep Ab | A hepatitis c virus non-structural ns3/4a fusion gene |
| US7022830B2 (en) * | 2000-08-17 | 2006-04-04 | Tripep Ab | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene |
| EP2258712A3 (en) * | 2002-03-15 | 2011-05-04 | Multicell Immunotherapeutics, Inc. | Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs |
| EP2572715A1 (en) * | 2002-12-30 | 2013-03-27 | 3M Innovative Properties Company | Immunostimulatory Combinations |
-
2006
- 2006-10-05 DE DE602006014720T patent/DE602006014720D1/de active Active
- 2006-10-05 WO PCT/ES2006/000554 patent/WO2007042583A1/es not_active Ceased
- 2006-10-05 EP EP06830863A patent/EP1949913B1/en active Active
- 2006-10-05 JP JP2008534032A patent/JP2009511452A/ja active Pending
- 2006-10-05 RU RU2008117328/15A patent/RU2431499C2/ru not_active IP Right Cessation
- 2006-10-05 CA CA2625506A patent/CA2625506C/en not_active Expired - Fee Related
- 2006-10-05 RS RSP-2010/0373A patent/RS51402B/sr unknown
- 2006-10-05 US US12/083,217 patent/US20100047231A1/en not_active Abandoned
- 2006-10-05 CN CN2006800457078A patent/CN101330928B/zh not_active Expired - Fee Related
- 2006-10-05 PL PL06830863T patent/PL1949913T3/pl unknown
- 2006-10-05 SI SI200630732T patent/SI1949913T1/sl unknown
- 2006-10-05 HR HR20100473T patent/HRP20100473T1/hr unknown
- 2006-10-05 PT PT06830863T patent/PT1949913E/pt unknown
- 2006-10-05 ES ES06830863T patent/ES2346570T3/es active Active
- 2006-10-05 AU AU2006301171A patent/AU2006301171B9/en not_active Ceased
- 2006-10-05 BR BRPI0616978-3A patent/BRPI0616978A2/pt not_active IP Right Cessation
- 2006-10-05 AT AT06830863T patent/ATE469657T1/de active
- 2006-10-05 DK DK06830863.4T patent/DK1949913T3/da active
-
2010
- 2010-08-19 CY CY20101100769T patent/CY1110744T1/el unknown
-
2013
- 2013-09-27 US US14/039,269 patent/US20140056943A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101479375B (zh) | Cd40激动剂抗体/1型干扰素协同佐剂组合、包含前述的结合物及其作为增强细胞免疫的治疗剂的用途 | |
| Krieg | Antiinfective applications of toll-like receptor 9 agonists | |
| JP5745577B2 (ja) | Ｃｄ４０アゴニスト抗体／ｉ型インターフェロン相乗性アジュバントの結合体、それを含む複合体、および細胞性免疫を強化する治療としてのその使用 | |
| Murad et al. | CPG-7909 (PF-3512676, ProMune®): Toll-like receptor-9 agonist in cancer therapy | |
| JP2009511452A5 (enExample) | ||
| US20140056943A1 (en) | Immuno-stimulant combination for prophylaxis and treatment of hepatitis c | |
| Osada et al. | Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects | |
| Chan et al. | The roles of MHC class II, CD40, and B7 costimulation in CTL induction by plasmid DNA | |
| Kang et al. | The adjuvant effect of levamisole on killed viral vaccines | |
| Gehring et al. | Type 1 interferon augments DNA‐based vaccination against hepatitis C virus core protein | |
| Yang et al. | Role of toll‐like receptors in the pathogenesis of COVID‐19: Current and future perspectives | |
| Liu et al. | Peptide vaccination of mice immune to LCMV or vaccinia virus causes serious CD8+ T cell-mediated, TNF-dependent immunopathology | |
| RU2639504C2 (ru) | Химерные антигены для вакцины против вируса гепатита с | |
| Mansilla et al. | Immunization against hepatitis C virus with a fusion protein containing the extra domain A from fibronectin and the hepatitis C virus NS3 protein | |
| Garcia et al. | An overview of hepatitis C vaccines | |
| EP2030628B1 (en) | A peptide for preventing or treating liver damage and its derivant and the use | |
| Weinberg | The role of OX40 (CD134) in T-cell memory generation | |
| Poordad et al. | Developments in hepatitis C therapy during 2000–2002 | |
| WO2011063133A1 (en) | LOW ANTIGEN-DOSE IMMUNIZATION FOR MAXIMIZING T-HELPER CELL 1 (T h1) IMMUNITY AGAINST DISEASE | |
| EP3134118A1 (en) | Particulate vaccine formulations for inducing innate and adaptive immunity | |
| EP2992898A1 (en) | T-cell adjuvant and its use for therapeutic or prophylactic vaccination | |
| Mishra et al. | Immunotherapy in liver diseases: a balance between immunity and tolerance | |
| KR20040028924A (ko) | Ｄｎａ와 항원의 조합에 의해 효능이 증강된 백신포뮬레이션 | |
| Immunotherapy | Divergent Roles for CD4 | |
| Garcin et al. | PS1-079. Differentiation of monocytes into dendritic cells is differentially induced by IFN-α/ω and IFN-β |